112 related articles for article (PubMed ID: 8647233)
1. A phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood hematopoietic progenitor cells.
Roman-Unfer S; Bitran JD; Garrison L; Proeschel C; Hanauer S; Schroeder L; Johnson L; Klein L; Martinec J
Exp Hematol; 1996 Jun; 24(7):823-8. PubMed ID: 8647233
[TBL] [Abstract][Full Text] [Related]
2. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
[TBL] [Abstract][Full Text] [Related]
3. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
[TBL] [Abstract][Full Text] [Related]
4. Mobilization of peripheral blood progenitor cells by cyclophosphamide and rhGM-CSF in multiple myeloma.
Martínez E; Sureda A; Dalmases CD; Sánchez JA; Amill B; Tugues D; Sardá P; Miralles A; Brunet S; Domingo-Albós A; García J
Bone Marrow Transplant; 1996 Jul; 18(1):1-7. PubMed ID: 8831988
[TBL] [Abstract][Full Text] [Related]
5. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
[TBL] [Abstract][Full Text] [Related]
6. In vitro production of megakaryocytes from PIXY321 versus GM-CSF-mobilized peripheral blood progenitor cells.
Lefebvre P; Winter JN; Rademaker AW; Goolsby C; Cohen I
Stem Cells; 1997; 15(2):112-8. PubMed ID: 9090787
[TBL] [Abstract][Full Text] [Related]
7. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
[TBL] [Abstract][Full Text] [Related]
9. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
[TBL] [Abstract][Full Text] [Related]
10. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
[TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
[TBL] [Abstract][Full Text] [Related]
12. Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment.
Glück S; Ross AA; Layton TJ; Ostrander AB; Goldstein LC; Porter K; Ho AD
Biol Blood Marrow Transplant; 1997 Dec; 3(6):316-23. PubMed ID: 9502299
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
[TBL] [Abstract][Full Text] [Related]
14. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
Ballester OF; Agaliotis DP; Hiemenz JW; Janssen WE; Fields KK; Zorksy PE; Goldstein SC; Perkins JB; Elfenbein GJ
Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
Passos-Coelho JL; Braine HG; Davis JM; Huelskamp AM; Schepers KG; Ohly K; Clarke B; Wright SK; Noga SJ; Davidson NE
J Clin Oncol; 1995 Mar; 13(3):705-14. PubMed ID: 7533827
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
Mahendra P; Johnson D; Scott MA; Jestice HK; Hood IM; Ager S; Bass G; Barker P; Boraks PA; Bloxham DM; Baglin TP; Marcus RE
Bone Marrow Transplant; 1996 Apr; 17(4):503-7. PubMed ID: 8722346
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells.
Basser RL; To LB; Begley CG; Juttner CA; Maher DW; Szer J; Cebon J; Collins JP; Russell I; Olver I
Clin Cancer Res; 1995 Jul; 1(7):715-21. PubMed ID: 9816037
[TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin and chemokine mRNA expression in patient post-chemotherapy and in vitro cytokine-treated marrow stromal cell layers.
Schwartz GN; Kammula U; Warren MK; Park MK; Yan XY; Marincola FM; Gress RE
Stem Cells; 2000; 18(5):331-42. PubMed ID: 11007917
[TBL] [Abstract][Full Text] [Related]
19. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.
Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S
Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727
[TBL] [Abstract][Full Text] [Related]
20. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
